Wilmington PLC APM sold for EUR 26 million

RNS Number : 1846M

Wilmington PLC

26 April 2024

 

26 April 2024

 

Wilmington plc

 

APM sold for €26 million

 

Wilmington plc (LSE: WIL, 'Wilmington', 'the Group'), the provider of data, information, education and training in the global Governance, Risk and Compliance markets, has sold its French healthcare business, APM, for an enterprise value of €26 million in cash, subject to customary working capital adjustments, to Philia Medical Editions SAS, a subsidiary of Europa Group.

 

For the year ended 30 June 2023, APM had gross assets of €9.6 million and reported a profit before tax of €2.3 million. The proceeds of the sale will be used for general corporate purposes.

 

Mark Milner, Chief Executive Officer of Wilmington, said

 

"This sale reflects our continued and active management of our portfolio as we assess the potential of each business to exhibit the six common Wilmington characteristics that we recognise as key drivers of organic revenue growth and profitability improvement."

 

Marc Doncieux, Chairman and co-Founder of Europa Group, said

 

"APM's entry into Europa Group is a major asset in consolidating our position as the French leader in training and health information. APM is a key player in our market, whose reputation for excellence and independence is perfectly in line with Europa Group's global strategy. We are delighted to welcome them on board!"

 

For further information, contact:

  

Wilmington plc   Mark Milner, Chief Executive Officer Guy Millward, Chief Financial Officer   Meare Consulting Adrian Duffield

020 7490 0049       07990 858548

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for data, information, education and training in the global Governance, Risk and Compliance (GRC) markets. Wilmington employs close to 1,000 people and sells to around 120 countries. Wilmington is listed on the main market of the London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DISUNONRSBUSURR